is a Managing Director in Basel, Switzerland.
Prior to joining Novartis Venture Fund, he worked as head Novartis Pharmaceutical Corporate M&A and Head Nervous System Business Development & Licensing. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche headquarters before joining Novartis. Markus received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley. Markus serves on the boards of eFFECTOR, Ra Pharmaceuticals and Trellis RSV Holdings, Inc.
Exits: Acorda Therapeutics, Inc. (NASDAQ: ACOR), EraGen Biosciences, Inc. (Acquired by Luminex Corporation), FoldRx Pharmaceuticals, Inc. (Acquired by Pfizer), Intellikine, Inc. (Acquired by Takeda), LigoCyte Pharmaceuticals, Inc. (Acquired by Takeda), Sirtris Pharmaceuticals, Inc. (Acquired by GlaxoSmithKline), Xenoport, Inc. (NASDAQ: XNPT).
eFFECTOR Therapeutics, Inc. (Board Seat)
Ra Pharmaceuticals, Inc. (Board Seat)
Trellis RSV Holdings, Inc. (Board Seat)